A point mutation leads to a single amino acid substitution at either position 12, 13 or 61. These mutations are found in over 90% of patients with pancreatic carcinomas, in 40% of patients with colorectal cancers and their preneoplastic lesions, in acute myeloid leukemia (AML) and in preleukemic syndromes.